Hepatitis Forums
Advanced Liver Disease Main Forums => Advanced Liver Disease => Topic started by: Hep Editors on June 24, 2020, 02:39:05 pm
-
A triple combination of two immunotherapy drugs plus a targeted therapy led to better responses than a double regimen in people with advanced liver cancer, according to a study presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium last month in San Francisco. However, adding more drugs also increased side effects, and more research is needed to weigh the risks and benefits of this approach.
Over years or decades, chronic hepatitis B or C, heavy alcohol use, fatty liver disease and other causes can lead to the development of liver cirrhosis and hepatocellular carcinoma (HCC), the most common type of liver cancer. This cancer is often detected late and is difficult to treat. Although it generally does not respond well to chemotherapy, several new immunotherapies and targeted therapies have been approved for HCC in recent years.
Read more...
https://www.hepmag.com/article/threedrug-immunotherapy-combo-shrinks-liver-tumors